Home › Research › Health systems and care delivery
Prevalence of Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) in the United States Medicare population
Haixin Zhang, Quanwu Zhang, Amir Abbas Tahami Monfared. Alzheimer s & Dementia, 2023-12-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Abstract Background Alzheimer’s disease (AD) is a chronic, neurodegenerative health condition. Mild cognitive impairment (MCI) is characterized by cognitive decline, without dementia. We aimed to estimate the prevalence of AD and MCI among Medicare beneficiaries. Method Patients were identified from the US Center for Medicare and Medicaid Services (CMS) database using International Classification of Diseases (ICD) codes for AD (331.0, G30.9, G30.8, or G30.1,) and MCI (331.83 or G31.84). Both AD and MCI were identified using the search rule of 2 ICD codes ≥30 days apart ≤365 days from both Medicare fee‐for‐service (FFS: 2008‐2018) and Medicare Advantage (MA: 2015‐2018). US regions were derived using zip codes and categorized by National Center for Chronic Disease Prevention/Health Promotion regions. Yearly prevalence was defined as the number of cases of AD or MCI in each year divided by the Medicare population in the year. Confidence intervals were not reported due to small intervals. Result The prevalence of AD and MCI was 1.9% and 0.1% (2008), 2.5 and 0.2% (2009), 2.7 and 0.2% (2010), 2.7 and 0.3% (2011), 2.8 and 0.4% (2012), 2.8 and 0.5% (2013), 2.8 and 0.6% (2014), 2.8 and 0.7% (2015), 2.3 and 0.7% (2016), 2.4 and 0.9% (2017), and 2.3 and 1% (2018), respectively. About 1.2 million AD patients and 490,000 MCI patients were identified in 2018. The prevalence of AD vs MCI among demographic subgroups in 2018 was 1.81% vs 0.85% (men) and 2.75% vs 1.03% (women); 0.59% vs 0.35% (ages 65‐69 years), 1.16% vs 0.65% (70‐74 years), 2.45% vs 1.19% (75‐79 years), 4.56% vs 1.86% (80‐84 years), and 8.71% vs 2.67% (≥85 years); 2.46% vs 1.05% (Whites), 1.87% vs 0.54% (Blacks), and 2.18% vs 0.58% (Asians). The prevalence of AD vs MCI in 2018 was highest in the US Northeast, especially in New Hampshire (3.25% vs 1.64%), Maryland (3.23% vs 1.45%) and New Jersey (3.43% vs 1.40%). Conclusion Among Medicare beneficiaries from 2008 to 2018, AD prevalence was generally stable, while MCI increased. Women, older age, White race, and Northeast region were associated with higher prevalence of AD and MCI in 2018.
What this study adds
Evidence grade: Low
This study estimated the prevalence of Alzheimer's disease and mild cognitive impairment among Medicare beneficiaries, finding that about 1.2 million Alzheimer's disease patients and 490,000 mild cognitive impairment patients were identified in 2018. Reported effect size: 1.9%; 0.1%; 0.2%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Zhang, H., Zhang, Q., & Monfared, A. A. T. (2023). Prevalence of Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) in the United States Medicare population. Alzheimer s & Dementia. https://doi.org/10.1002/alz.077079
Vancouver
Zhang H, Zhang Q, Monfared AAT. Prevalence of Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) in the United States Medicare population. Alzheimer s & Dementia. 2023. doi:10.1002/alz.077079.
BibTeX
@article{zhang2023-28dad969,
author = {Zhang, Haixin and Zhang, Quanwu and Monfared, Amir Abbas Tahami},
title = {{Prevalence of Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) in the United States Medicare population}},
journal = {Alzheimer s \& Dementia},
year = {2023},
doi = {10.1002/alz.077079},
url = {https://doi.org/10.1002/alz.077079}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Result The prevalence of AD and MCI was 1.9% and 0.1% (2008), 2.5 and 0.2% (2009), 2.7 and 0.2% (2010), 2.7 and 0.3% (2011), 2.8 and 0.4% (2012), 2.8 and 0.5% (2013), 2.8 and 0.6% (2014), 2.8 and 0.7% (2015), 2.3 and 0.7% (2016), 2.4 and 0.9% (2017), and 2.3 and 1% (2018), respectively.
- Women, older age, White race, and Northeast region were associated with higher prevalence of AD and MCI in 2018.
Why it matters
This study estimated the prevalence of Alzheimer's disease and mild cognitive impairment among Medicare beneficiaries, finding that about 1.2 million Alzheimer's disease patients and 490,000 mild cognitive impairment patients were identified in 2018. Women, older age, White race, and Northeast region were associated with higher prevalence of Alzheimer's disease and mild cognitive impairment in 2018.
Study details
- Effect size1.9%; 0.1%; 0.2%
- Evidence strengthLow
How this study scored 32/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.2 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 1 / 6 | Cited 0.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Amir Abbas Tahami Monfared: h-index 20 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Eisai (United States): institution h-index 251 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Total | 32 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Health systems and care delivery from nearby years
Also tagged “mini-mental”
840 studies in the library carry the topic tag “mini-mental”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 840 tagged studies.